Amedisys (NASDAQ:AMED) Earns “Outperform” Rating from Royal Bank of Canada

Amedisys (NASDAQ:AMED)‘s stock had its “outperform” rating reaffirmed by investment analysts at Royal Bank of Canada in a report issued on Wednesday,Benzinga reports. They currently have a $100.00 price target on the health services provider’s stock. Royal Bank of Canada’s price target indicates a potential upside of 8.98% from the company’s previous close.

Separately, Stephens reiterated an “equal weight” rating and set a $101.00 target price on shares of Amedisys in a research report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $100.75.

Amedisys Trading Down 0.2 %

Amedisys stock opened at $91.76 on Wednesday. The firm has a market capitalization of $3.01 billion, a price-to-earnings ratio of 36.41, a P/E/G ratio of 1.78 and a beta of 0.89. Amedisys has a 12-month low of $82.15 and a 12-month high of $98.95. The firm has a 50 day moving average of $92.16 and a 200 day moving average of $91.94. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED) last released its earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The firm had revenue of $598.05 million for the quarter, compared to analysts’ expectations of $602.38 million. As a group, research analysts predict that Amedisys will post 4.4 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in AMED. MassMutual Private Wealth & Trust FSB lifted its position in shares of Amedisys by 56.1% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 334 shares of the health services provider’s stock worth $31,000 after buying an additional 120 shares in the last quarter. Fifth Third Bancorp increased its stake in Amedisys by 68.1% in the 1st quarter. Fifth Third Bancorp now owns 348 shares of the health services provider’s stock worth $32,000 after acquiring an additional 141 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Amedisys by 55.1% during the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock worth $34,000 after acquiring an additional 124 shares in the last quarter. UMB Bank n.a. boosted its position in shares of Amedisys by 100.0% during the 1st quarter. UMB Bank n.a. now owns 386 shares of the health services provider’s stock valued at $36,000 after acquiring an additional 193 shares during the last quarter. Finally, HBW Advisory Services LLC purchased a new position in shares of Amedisys in the fourth quarter valued at $38,000. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.